Lisata Therapeutics Company Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.

Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.

Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc.

Country	United States
Founded	1980
Industry	Biological Products, Except Diagnostic Substances
Employees	25
CEO	David Mazzo

Contact Details

Address: 110 Allen Road Basking Ridge, Delaware 07920 United States
Phone	908 842 0100
Website	lisata.com

Stock Details

Ticker Symbol	0HS8
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.	President, Chief Executive Officer and Director
Dr. Kristen K. Buck M.D.	Executive Vice President of Research & Development and Chief Medical Officer
James Nisco	Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer
Tariq Imam	Vice President of Business Development and Operations and Corporate Counsel
Gregory S. Berkin	Chief Information and Data Protection Officer
John D. Menditto	Vice President of Investor Relations and Corporate Communications
Gail Holler	Vice President of Human Resources
Dr. William K. Sietsema Ph.D.	Vice President of Global Regulatory Affairs